Antiobesity effect of MK-5046, a novel bombesin receptor subtype-3 agonist.

Abstract

Bombesin receptor subtype-3 (BRS-3) is an orphan G protein-coupled receptor implicated in the regulation of energy homeostasis. Here, we report the biologic effects of a highly optimized BRS-3 agonist, (2S)-1,1,1-trifluoro-2-[4-(1H-pyrazol-1-yl)phenyl]-3-(4-{[1-(trifluoromethyl)cyclopropyl]methyl}-1H-imidazol-2-yl)propan-2-ol (MK-5046). Single oral doses of MK-5046 inhibited 2-h and overnight food intake and increased fasting metabolic rate in wild-type but not Brs3 knockout mice. Upon dosing for 14 days, MK-5046 at 25 mg · kg(-1) · day(-1) reduced body weight of diet-induced obese mouse by 9% compared with vehicle-dosed controls. In mice, 50% brain receptor occupancy was achieved at a plasma concentration of 0.34 ± 0.23 μM. With chronic dosing, effects on metabolic rate, rather than food intake, seem to be the predominant mechanism for weight reduction by MK-5046. The compound also effectively reduced body weight in rats and caused modest increases in body temperature, heart rate, and blood pressure. These latter effects on temperature, heart rate, and blood pressure were transient in nature and desensitized with continued dosing. MK-5046 is the first BRS-3 agonist with properties suitable for use in larger mammals. In dogs, MK-5046 treatment produced statistically significant and persistent weight loss, which was initially accompanied by increases in body temperature and heart rate that abated with continued dosing. Our results demonstrate antiobesity efficacy for MK-5046 in rodents and dogs and further support BRS-3 agonism as a new approach to the treatment of obesity.

• Authors: Xiao-Ming Guan, Joseph M Metzger, Liming Yang, Kate A Raustad, Sheng-Ping Wang, Stephanie K Spann, Jennifer A Kosinski, Hong Yu, Lauren P Shearman, Terry D Faidley, Oksana Palyha, Yanqing Kan, Theresa M Kelly, Iyassu Sebhat, Linus S Lin, Jasminka Dragovic, Kathy A Lyons, Stephanie Craw, Ravi P Nargund, Donald J Marsh, Alison M Strack, Marc L Reitman
• Journal: The Journal of pharmacology and experimental therapeutics (J Pharmacol Exp Ther) Vol. 336 Issue 2 Pg. 356-64 (Feb 2011) ISSN: 1521-0103 [Electronic] United States
• PMID: 21036912 (Publication Type: Journal Article)

Chemical References

• 1,1,1-trifluoro-2-(4-(1H-pyrazol-1-yl)phenyl)-3-(4-((1-(trifluoromethyl)cyclopropyl)methyl)-1H-imidazol-2-yl)propan-2-ol
• Anti-Obesity Agents
• Imidazoles
• Pyrazoles
• Receptors, Bombesin
• bombesin receptor subtype 3

Topics

• Animals
• Anti-Obesity Agents (pharmacology)
• Blood Pressure (drug effects)
• Body Weight (drug effects)
• Dogs
• Dose-Response Relationship, Drug
• Eating (drug effects)
• Energy Metabolism (drug effects)
• Heart Rate (drug effects)
• Imidazoles (pharmacology)
• Male
• Mice
• Mice, Inbred C57BL
• Pyrazoles (pharmacology)
• Rats
• Rats, Sprague-Dawley
• Receptors, Bombesin (agonists, analysis)